OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q3 2021. The put-call ratio across all filers is 0.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $10 | -99.9% | 3,390 | 0.0% | 0.01% | -28.6% |
| Q3 2022 | $14,000 | 0.0% | 3,390 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $14,000 | -17.6% | 3,390 | 0.0% | 0.01% | -12.5% |
| Q1 2022 | $17,000 | -29.2% | 3,390 | 0.0% | 0.01% | -27.3% |
| Q4 2021 | $24,000 | 0.0% | 3,390 | +41.8% | 0.01% | 0.0% |
| Q3 2021 | $24,000 | -29.4% | 2,390 | 0.0% | 0.01% | -31.2% |
| Q2 2021 | $34,000 | +61.9% | 2,390 | +91.2% | 0.02% | +33.3% |
| Q1 2021 | $21,000 | -19.2% | 1,250 | 0.0% | 0.01% | -29.4% |
| Q4 2020 | $26,000 | +160.0% | 1,250 | 0.0% | 0.02% | +112.5% |
| Q3 2020 | $10,000 | 0.0% | 1,250 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $10,000 | +66.7% | 1,250 | 0.0% | 0.01% | +33.3% |
| Q1 2020 | $6,000 | -40.0% | 1,250 | -50.4% | 0.01% | -14.3% |
| Q4 2019 | $10,000 | +25.0% | 2,518 | 0.0% | 0.01% | +16.7% |
| Q3 2019 | $8,000 | -27.3% | 2,518 | 0.0% | 0.01% | -33.3% |
| Q2 2019 | $11,000 | – | 2,518 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |